SLC5A2 and chronic kidney disease: Subgroup analyses reveal that, among CKD patients with an eGFR above 45 mL/min/1.73 m2, SGLT2 inhibitors are more effective in mitigating adverse renal outcomes compared to patients with lower eGFR levels.